Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records

By sjmartinez • August 4, 2023

Beaufils M, Amodru V, Tejeda M, Boher JM, Zemmour C, Chanez B, Chrétien AS, Gorvel L, Gravis G, Bruyat D, Mari R, Madroszyk A, Cuny T, Gonçalves A, Lisberg AE, Olive D, Tassy L, Castinetti F, Rochigneux P. Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records. J Immunother Cancer. 2023 Aug;11(8):e006786. doi: 10.1136/jitc-2023-006786. PMID: 37536938.

Tags: Hematology/Oncology, immune checkpoint inhibitors, immunotherapy, Publications

Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer

Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, Ryg U, Schulz-Jaavall M, Weidhaas JB, Santoso M, Parmisano S, Calais J, Reiter[...]

Immune Checkpoint Inhibitor Myocarditis Masquerading as Brugada Syndrome

Talishinsky A, Bachour K, Lin C, Zakka P, Bassam K, Bull L, Garon E, Krokhaleva Y, Hanna P, Yang EH. Immune Checkpoint Inhibitor Myocarditis Masquerading[...]

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial

Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Prusty S, Nelson S, DuPage A, Thompson A, Koralek DO, Sison EAR, Rha SY. Domvanalimab and zimberelimab[...]